stockrow
Saturday 7 November 2026
Export NBTX’s income statement to Excel — free account
Nanobiotix S.A. - Sponsored ADR
NBTX Healthcare Biotechnology
Nanobiotix S.A. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $36.9 million.
30.63
0.61
+2.03%
Follow NBTX
Alert me
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
0.89 | 0.49 | 0.95 | 1.31 | |
Current Ratio |
1.04 | 0.63 | 1.09 | 1.44 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | — | |
Capex/Depreciation |
(0.52) | (0.20) | (0.36) | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | — | — | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | — | |
Capex per Share |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | — | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(22.07) | (19.94) | (38.42) | — | |
Working Capital |
2.74 | (26.28) | 5.93 | 43.66 | |
Capital Expenditures |
(0.91) | (0.18) | (0.61) | — | |
Net Current Asset Value |
(77.54) | (84.27) | (101.25) | (44.45) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
1.66 | 1.64 | 1.70 | 2.80 | |
Average Payables |
15.91 | 15.72 | 15.03 | 15.40 | |
Average Assets |
67.96 | 47.67 | 89.14 | 121.28 | |
Average Common Equity |
(49.80) | (68.46) | (48.79) | (31.13) |
Columns are period end dates · fundamentals updated 2 Nov 2026